Apeksha Patel
Family Medicine · Aliquippa, PANPI 1235587007
Payments from drug & device makers
Across 89 payments — averaging $14.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$133
- AstraZeneca$127
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$125
- Novo Nordisk$123
- AbbVie$109
- GSK$103
- plus $611 from 16 others
What the payments were for
- Food & beverage$1,30098%
- Education$292%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 9 | $133 |
| AstraZeneca | 8 | $127 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 11 | $125 |
| Novo Nordisk | 7 | $123 |
| AbbVie | 7 | $109 |
| GSK | 7 | $103 |
| Lilly USA, LLC | 6 | $97 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $82 |
| Johnson & Johnson | 4 | $73 |
| Pfizer | 4 | $56 |
| Amarin Pharma, Inc. | 3 | $53 |
| Amgen | 3 | $46 |
| Merck | 3 | $40 |
| Teva Pharmaceuticals USA, Inc. | 2 | $28 |
| Astellas Pharma US Inc | 1 | $24 |
| Scilex Pharmaceuticals Inc. | 1 | $22 |
| Bausch Health US, LLC | 1 | $19 |
| Ironshore Pharmaceuticals Inc. | 1 | $18 |
| Ironwood Pharmaceuticals, Inc | 1 | $15 |
| Arbor Pharmaceuticals, Inc. | 1 | $15 |
| Shire North American Group Inc | 1 | $13 |
| Hikma Pharmaceuticals USA | 1 | $11 |
How this compares
$1,329 in reported general payments places this provider in the 70th percentile of 4,967 family medicine providers in Pennsylvania.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 18 | $18,109 |
| PradaxaDabigatran Etexilate Mesylate | 59 | $12,164 |
| Liraglutide | 11 | $8,701 |
| Spiriva RespimatTiotropium Bromide | 13 | $6,747 |
| Atorvastatin Calcium | 372 | $4,520 |
| Wixela InhubFluticasone Propion/Salmeterol | 17 | $3,853 |
| Humulin N KwikpenInsulin Nph Human Isophane | 27 | $2,906 |
| Humulin NInsulin Nph Human Isophane | 12 | $2,755 |
| Lisinopril | 225 | $2,574 |
| Amlodipine Besylate | 201 | $2,470 |
| Levothyroxine Sodium | 131 | $2,450 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 97 | $1,821 |
| Losartan Potassium | 145 | $1,767 |
| Rosuvastatin Calcium | 129 | $1,485 |
| Trazodone Hcl | 94 | $1,357 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimPradaxa, Spiriva Respimat | $133 | $18,91172 claims |
| PfizerEliquis | $56 | $18,10918 claims |
| Lilly USA, LLCHumulin N | $97 | $2,75512 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 4,967 family medicine providers in Pennsylvania.
Other family medicine in Aliquippa
- Kem YenalPhila$12.6M
- Marcy FleckerSmithfield$6.9M
- Tiffany PlutoScottdale$4.8M
- Bryce PalchickPittsburgh$4.7M
- Harris CohenHorsham$3.7M
- Shari RozenPittsburgh$2.9M
- Richard CookUniontown$2.1M
- Bruce GebhardtErie$2.1M
- Peter CognettiScranton$1.9M
- Bradley FoxErie$1.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.